Antiplatelet agents for preventing pre-eclampsia and its complications

Area of Science:

• Obstetrics and Gynecology
• Pharmacology
• Clinical Trials

Background:

• Pre-eclampsia is linked to an imbalance in prostacyclin and thromboxane production.
• This imbalance suggests antiplatelet agents may prevent or delay pre-eclampsia.

Purpose of the Study:

• To evaluate the effectiveness and safety of antiplatelet agents for preventing pre-eclampsia in at-risk women.

Main Methods:

• Systematic review and meta-analysis of 59 randomized controlled trials involving 37,560 women.
• Searched multiple databases including Cochrane Pregnancy and Childbirth Group's Trials Register and EMBASE.

Main Results:

• Antiplatelet agents reduced the risk of pre-eclampsia by 17% (NNT 72).
• Significant absolute risk reduction observed in high-risk women (NNT 19).
• Reduced risk of preterm birth, fetal/neonatal deaths, and small-for-gestational age infants.

Conclusions:

• Antiplatelet agents, primarily low-dose aspirin, offer moderate benefits in preventing pre-eclampsia and its adverse outcomes.
• Further research is needed to determine optimal patient selection, treatment timing, and dosage.